63 research outputs found
First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
A rare case of cellular epithelioid hemangioma involving the penis
http://deepblue.lib.umich.edu/bitstream/2027.42/175275/2/J Cutan Pathol - 2022 - Frecentese - A rare case of cellular epithelioid hemangioma involving the penis.pdfPublished versionDescription of J Cutan Pathol - 2022 - Frecentese - A rare case of cellular epithelioid hemangioma involving the penis.pdf : Published versio
ACL Injury Prevention Training Results in Modification of Hip and Knee Mechanics During a Drop-Landing Task
Identifying Soil and Transport Properties Using a Model of Infiltration-Redistribution Flow and Transport in the Unsaturated Zone
The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas
Abstract Anaplastic lymphoma kinase (ALK) is an oncogenic receptor tyrosine kinase that is activated by gene amplification and mutation in neuroblastomas. ALK inhibitors can delay the progression of ALK-driven cancers, but are of limited use owing to ALK inhibitor resistance. Here, we show that resistance to ALK inhibitor in ALK-driven neuroblastomas can be attenuated by combination treatment with a p53 activator. Either ALK inhibition or p53 activator treatment induced cell cycle arrest, whereas combination treatment induced apoptosis, and prevented tumour relapse both in vitro and in vivo. This shift toward apoptosis, and away from cell-cycle arrest, in the presence of an ALK inhibitor and a p53 activator, is mediated by inhibition of the ALK–AKT–FOXO3a axis leading to a specific upregulation of SOX4. SOX4 cooperates with p53 to upregulate the pro-apoptotic protein PUMA. These data therefore suggest a novel combination therapy strategy for treating ALK-driven neuroblastomas
Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment
Giving Way Event During a Combined Stepping and Crossover Cutting Task in an Individual With Anterior Cruciate Ligament Deficiency
- …